Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Northwest Biotherapeutics (NWBO) Shares Outstanding (2016 - 2025)

Northwest Biotherapeutics' Shares Outstanding history spans 15 years, with the latest figure at $1.6 billion for Q4 2025.

  • Quarterly results put Shares Outstanding at $1.6 billion for Q4 2025, up 17.97% from a year ago — trailing twelve months through Dec 2025 was $1.6 billion (up 17.97% YoY), and the annual figure for FY2025 was $1.6 billion, up 17.97%.
  • Shares Outstanding for Q4 2025 was $1.6 billion at Northwest Biotherapeutics, up from $1.5 billion in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $1.6 billion in Q4 2025 to a low of $842.4 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $1.1 billion (2023), against an average of $1.2 billion.
  • The sharpest move saw Shares Outstanding skyrocketed 127115.97% in 2021, then grew 7.8% in 2023.
  • Year by year, Shares Outstanding stood at $948.4 million in 2021, then grew by 12.65% to $1.1 billion in 2022, then grew by 10.02% to $1.2 billion in 2023, then rose by 13.03% to $1.3 billion in 2024, then increased by 17.97% to $1.6 billion in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $1.6 billion, $1.5 billion, and $1.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.